Advexin marketing application for rare cancer withdrawn in EU
This article was originally published in Scrip
Executive Summary
Gendux Molecular, the Irish subsidiary of the US firmIntrogen Therapeutics, has withdrawn the EU marketing application for the gene therapy Advexin (contusugene ladenovec) for the treatment of the rare Li-Fraumeni cancer.